—Newborn screening for spinal muscular atrophy allows for earlier diagnosis in preterm infants, leading to earlier use of disease-modifying therapies, in the presymptomatic stage, and better ...

Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

It is proposed that denervation in infantile muscle results in typical small rounded fibers and that this process, so different from that of adult neurogenic atrophy, is age-dependent.

One such condition is Spinal Muscular Atrophy (SMA), a genetic disorder affecting infants and young children, impacting their movement and muscle function. SMA is a genetic disorder of movement ...

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow. Novartis was ...

The mutation that causes Spinal Muscular Atrophy (SMA) can be detected in a ... panel suggest that if the cost of testing every infant is not outweighed by the benefit of early detection, then ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma ...

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...

Considering taking supplements to treat spinal muscular atrophy? Below is a list of common natural remedies used to treat or reduce the symptoms of spinal muscular atrophy. Follow the links to ...

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.